This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Entasis Therapeutics Holdings Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

90.2%

Ratio d'endettement

US$15.01m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$33.55m
Fonds propres	US$16.65m
Total du passif	US$27.44m
Total des actifs	US$44.09m

Mises à jour récentes de la santé financière

Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?

Dec 16

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Aug 19

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Dec 01

Recent updates

Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?

Dec 16

Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products

Nov 17

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Aug 19

Entasis Therapeutics shares rise after lining up ETX0462 poster presentation

Jun 18

What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?

Feb 17

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Dec 01

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ETTX ( $39.9M ) dépassent ses passifs à court terme ( $24.1M ).

Passif à long terme: Les actifs à court terme de ETTX ( $39.9M ) dépassent ses passifs à long terme ( $3.3M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: ETTX dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de ETTX a diminué au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ETTX dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: ETTX dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 10.6 % chaque année

This company has been acquired

Entasis Therapeutics Holdings Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Recent updates

Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from NASDAQ Composite Index

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell Microcap Value Index

Entasis Therapeutics Holdings Inc. Presents Data Highlights from Phase 3 Attack Trial At 2022 American Thoracic Society Annual Conference

Price target decreased to US$2.00

Forecast to breakeven in 2024

Price target decreased to US$2.65

Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference

Entasis Therapeutics Holdings Inc. Announces Executive Changes

Entasis Therapeutics Holdings Inc. announced that it has received $15 million in funding from Innoviva Strategic Opportunities LLC

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?

Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Entasis Therapeutics Holdings Inc. Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens

Entasis Therapeutics shares rise after lining up ETX0462 poster presentation

Entasis Therapeutics Holdings Inc. announced that it has received $20 million in funding from Innoviva Strategic Opportunities LLC

Price target decreased to US$6.00

Consensus forecasts updated

Entasis Therapeutics Holdings Inc. announced that it expects to receive $20 million in funding from Innoviva Strategic Opportunities LLC

What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?

Entasis Therapeutics Holdings Inc. Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S

New 90-day high: US$2.95

New 90-day high: US$2.72

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Earnings miss expectations

New 90-day low: US$1.83

New 90-day low: US$2.25

Entasis Therapeutics Holdings Inc. announced that it expects to receive $24.999999 million in funding from Innoviva, Inc., Armistice Capital LLC

Entasis Therapeutics Holdings Inc. announced that it expects to receive $28.108125 million in funding from Innoviva, Inc., and other investors

New 90-day low - US$2.51

Earnings released

New 90-day high - US$3.77

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines